Search Result

Pathways Recommended:	Stem Cell/Wnt Cell Cycle/DNA Damage

Results for "

colorectal cancer cells

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Acyltransferase (1) ADC Cytotoxin (2) Akt (9) Aldehyde Dehydrogenase (ALDH) (1) AMPK (3) Antibiotic (2) Apoptosis (51) Autophagy (17) Bacterial (1) Bcl-2 Family (2) BMI1 (2) c-Fms (2) c-Met/HGFR (2) c-Myc (1) Caspase (1) CD3 (1) CDK (4) Checkpoint Kinase (Chk) (1) Cholinesterase (ChE) (1) COX (2) CRAC Channel (1) CRM1 (2) CXCR (1) Cytochrome P450 (1) Deubiquitinase (3) Dihydroorotate Dehydrogenase (1) DNA/RNA Synthesis (7) EGFR (3) Endogenous Metabolite (8) Epigenetic Reader Domain (1) ERK (4) FAK (1) FAP (1) Fatty Acid Synthase (FASN) (2) Ferroptosis (1) FLAP (2) FLT3 (1) Fungal (3) Histone Demethylase (1) Histone Methyltransferase (3) HIV (1) HSP (3) HSV (2) Influenza Virus (5) Interleukin Related (1) Isotope-Labeled Compounds (2) Keap1-Nrf2 (1) KLF (2) mAChR (3) MAGL (1) MDM-2/p53 (1) MEK (4) MicroRNA (2) Microtubule/Tubulin (1) Mitochondrial Metabolism (1) MMP (2) Mps1 (1) NF-κB (4) NO Synthase (1) Notch (1) Nucleoside Antimetabolite/Analog (2) Orthopoxvirus (2) p38 MAPK (3) PARP (3) PD-1/PD-L1 (1) PDGFR (1) PI3K (5) Platelet-activating Factor Receptor (PAFR) (1) Porcupine (1) Potassium Channel (1) Prostaglandin Receptor (1) PROTACs (4) Pyruvate Kinase (2) Raf (4) Ras (10) Reactive Oxygen Species (4) ROS Kinase (1) Ser/Thr Protease (1) Serotonin Transporter (3) Somatostatin Receptor (2) Src (2) STAT (1) Survivin (2) TAM Receptor (1) Thymidylate Synthase (2) Tie (1) TNF Receptor (1) Topoisomerase (4) Trk Receptor (3) TRP Channel (1) ULK (1) VEGFR (2) Wnt (5) β-catenin (7)
By Research Areas:	Cancer (140) Cardiovascular Disease (2) Infection (6) Inflammation/Immunology (20) Metabolic Disease (5) Neurological Disease (8)

By Targets:

Acyltransferase (1)

ADC Cytotoxin (2)

Akt (9)

Aldehyde Dehydrogenase (ALDH) (1)

AMPK (3)

Antibiotic (2)

Apoptosis (51)

Autophagy (17)

Bacterial (1)

Bcl-2 Family (2)

BMI1 (2)

c-Fms (2)

c-Met/HGFR (2)

c-Myc (1)

Caspase (1)

CD3 (1)

CDK (4)

Checkpoint Kinase (Chk) (1)

Cholinesterase (ChE) (1)

COX (2)

CRAC Channel (1)

CRM1 (2)

CXCR (1)

Cytochrome P450 (1)

Deubiquitinase (3)

Dihydroorotate Dehydrogenase (1)

DNA/RNA Synthesis (7)

EGFR (3)

Endogenous Metabolite (8)

Epigenetic Reader Domain (1)

ERK (4)

FAK (1)

FAP (1)

Fatty Acid Synthase (FASN) (2)

Ferroptosis (1)

FLAP (2)

FLT3 (1)

Fungal (3)

Histone Demethylase (1)

Histone Methyltransferase (3)

HIV (1)

HSP (3)

HSV (2)

Influenza Virus (5)

Interleukin Related (1)

Isotope-Labeled Compounds (2)

Keap1-Nrf2 (1)

KLF (2)

mAChR (3)

MAGL (1)

MDM-2/p53 (1)

MEK (4)

MicroRNA (2)

Microtubule/Tubulin (1)

Mitochondrial Metabolism (1)

MMP (2)

Mps1 (1)

NF-κB (4)

NO Synthase (1)

Notch (1)

Nucleoside Antimetabolite/Analog (2)

Orthopoxvirus (2)

p38 MAPK (3)

PARP (3)

PD-1/PD-L1 (1)

PDGFR (1)

PI3K (5)

Platelet-activating Factor Receptor (PAFR) (1)

Porcupine (1)

Potassium Channel (1)

Prostaglandin Receptor (1)

PROTACs (4)

Pyruvate Kinase (2)

Raf (4)

Ras (10)

Reactive Oxygen Species (4)

ROS Kinase (1)

Ser/Thr Protease (1)

Serotonin Transporter (3)

Somatostatin Receptor (2)

Src (2)

STAT (1)

Survivin (2)

TAM Receptor (1)

Thymidylate Synthase (2)

Tie (1)

TNF Receptor (1)

Topoisomerase (4)

Trk Receptor (3)

TRP Channel (1)

ULK (1)

VEGFR (2)

Wnt (5)

β-catenin (7)

By Research Areas:

Cancer (140)

Cardiovascular Disease (2)

Infection (6)

Inflammation/Immunology (20)

Metabolic Disease (5)

Neurological Disease (8)

141

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Cibisatamab	CD3	Cancer
Cibisatamab (CEA-TCB), a T cell bispecific antibody, binds Carcino-Embryonic Antigen (CEA) on cancer cells and CD3 on T cells. Cibisatamab (CEA-TCB) triggers T cell killing of cancer cell lines expressing moderate to high levels of CEA at the cell surface. Cibisatamab (CEA-TCB) can be used for colorectal cancer research .

(-)-Epigallocatechin Gallate 30+ Cited Publications EGCG; Epigallocatechol Gallate	Endogenous Metabolite Apoptosis	Inflammation/Immunology Cancer
(-)-Epigallocatechin Gallate (EGCG) is a major polyphenol in green tea, which can inhibit cell proliferation and induce cell apoptosis. (-)-Epigallocatechin Gallate inhibits glutamate dehydrogenase 1/2 (GDH1/2, GLUD1/2) activity. (-)-Epigallocatechin Gallate has a potent anticancer, antioxidant and anti-inflammatory properties against various types of cancers such as colorectal cancer, myeloid leukemia, thyroid carcinoma .

TNIK-IN-5	Wnt	Cancer
TNIK-IN-5 is an efficient TNIK inhibitor with IC₅₀ of 0.05 μM. TNIK-IN-5 efficiently inhibits Wnt signaling in intact cells. TNIK-IN-5 shows excellent in vitro anti-colorectal cancer activity .

PROTAC TTK degrader-1	PROTACs	Cancer
PROTAC TTK degrader-1 is a potent TTK (threonine tyrosine kinase) PROTAC degrader, with DC₅₀ values of 1.7 and 5.8 nM in COLO-205 and HCT-116 cell, respectively. PROTAC TTK degrader-1 exhibits target degradation and anticancer efficacy in a xenograft mouse model of COLO-205 human colorectal cancer cells .

NSC666715	DNA/RNA Synthesis	Cancer
NSC666715 is a strand-displacement activity of DNA polymerase inhibitor. NSC666715 potentiates Temozolomide (HY-17364)-induced DNA damage, cell senescence and apoptosis. NSC666715 can be used for study colorectal cancer .

CRM1-IN-1	CRM1	Cancer
CRM1-IN-1 (Compound KL1) is a noncovalent CRM1 inhibitor. CRM1-IN-1 induces nuclear CRM1 degradation (IC₅₀: 0.27 μM). CRM1-IN-1 inhibits CRM1-mediated nuclear export and cell proliferation, and triggers apoptosis in colorectal cancer cells .

KRASG12C IN-13	Others	Cancer
KRASG12C IN-13 (LY3499446) is a potent KRAS G12C inhibitor. KRASG12C IN-13 is promising for research of advanced solid tumors including non-small cell lung cancer and colorectal cancer .

LSN3074753	Raf	Cancer
LSN3074753, an analog of LY3009120 (HY-12558), is a pan-RAF and Raf dimer inhibitor. LSN3074753 demonstrates activity against tumor cells with MAPK pathway activation driven by BRAF monomer or RAF dimers including BRAF- or KRAS-mutant colorectal cancer. LSN3074753 combined with Cetuximab (HY-P9905) shows additive and synergistic effects for colorectal cancer PDX models, particularly those with KRAS or BRAF mutation .

CTL-06	Fatty Acid Synthase (FASN)	Cancer
CTL-06 is an inhibitor of Fatty Acid Synthase (FASN) (IC₅₀: 3 μM) and can induce apoptosis. CTL-12 blocks the cell cycle in the Sub-G1/S phase, upregulates the expression of caspase-9 and the apoptosis marker Bax, and downregulates the anti-apoptotic marker Bcl-xL. CTL-12 inhibits de novo lipogenesis, blocks the metabolic demands of tumor cells, and is commonly used in breast and colorectal cancer research .

PROTAC TTK degrader-2	PROTACs	Cancer
PROTAC TTK degrader-2 is a potent TTK (threonine tyrosine kinase) PROTAC degrader, with DC₅₀ values of 3.1 and 12.4 nM in COLO-205 and HCT-116 cell, respectively. PROTAC TTK degrader-2 exhibits target degradation and anticancer efficacy in a xenograft mouse model of COLO-205 human colorectal cancer cells .

CTL-12	Fatty Acid Synthase (FASN)	Cancer
CTL-12 is an inhibitor of fatty acid synthase (FASN) (IC₅₀: 2.5 μM) and can induce apoptosis. CTL-12 blocks the cell cycle in the Sub-G1/S phase, upregulates the expression of caspase-9 and the apoptosis marker Bax, and downregulates the anti-apoptotic marker Bcl-xL. CTL-12 inhibits de novo lipogenesis, blocks the metabolic demands of tumor cells, and is commonly used in breast and colorectal cancer research .

EGCG-4″-sulfate	Endogenous Metabolite Apoptosis	Inflammation/Immunology Cancer
EGCG-4″-sulfate is a major polyphenol in green tea, which can inhibit cell proliferation and induce cell apoptosis. (-)-Epigallocatechin Gallate sulfate inhibits glutamate dehydrogenase 1/2 (GDH1/2, GLUD1/2) activity. EGCG-4″-sulfate has a potent anticancer, antioxidant and anti-inflammatory properties against various types of cancers such as colorectal cancer, myeloid leukemia, thyroid carcinoma .

UU-T02 1 Publications Verification	β-catenin Wnt	Metabolic Disease Cancer
UU-T02 is a novel potent, selective small-molecule inhibitor of β-Catenin/T-cell factor protein-protein interaction (β-catenin/Tcf PPI) with a K_i of 1.36 μM . UU-T02 inhibits canonical Wnt signaling and the growth of colorectal cancer cells .

Ethoxysanguinarine 1 Publications Verification	Apoptosis	Cancer
Ethoxysanguinarine is a benzophenanthridine alkaloid natural product that is mainly found in Macleaya cordata. Ethoxysanguinarine is an inhibitor of protein phosphatase 2A (CIP2A). Ethoxysanguinarine induces cell apoptosis and inhibits colorectal cancer cells growth .

Petosemtamab MCLA 158	EGFR	Cancer
Petosemtamab (MCLA 158) is an anti- EGFR (K_d: 0.22 nM) and anti-LGR5 (K_d: 0.86 nM) monoclonal antibody (mAb). Petosemtamab leads to EGFR signaling blockade and receptor degradation in LGR5+ cancer cells. Petosemtamab can be used in the research of solid tumors, such as head and neck squamous cell carcinoma (HNSCC), metastatic colorectal cancer (CRC) .

β-catenin-IN-37	β-catenin	Cancer
β-catenin-IN-37 is a selective *β-Catenin/T-cell* factor protein-protein interaction** (β-catenin/Tcf PPI) inhibitor. β-catenin-IN-37 inhibits canonical Wnt signaling and the growth of colorectal cancer cells SW480 and HCT116 with the IC₅₀ values of 20 μM and 31 μM, respectively .

Patritumab 1 Publications Verification Human Anti-ERBB3 Recombinant Antibody	EGFR Akt ERK PARP Survivin	Cancer
Patritumab (Human Anti-ERBB3 Recombinant Antibody) is a neutralizing monoclonal antibody to ERBB3. Patritumab shows a synergy with Cetuximab (HY-P9905), potently inhibits the phosphorylation of EGFR, HER2, HER3, ERK, and AKT. Patritumab also induces cell apoptosis and suppresses the growth of pancreatic, non-small cell lung cancer, and colorectal cancer xenograft tumors .

Autophagy-IN-1	Autophagy Apoptosis	Cancer
Autophagy-IN-1 is a potent autophagy/mitophagy inhibitor, acts by selectively increasing the autophagic flux while blocking the autophagosome-lysosome fusion in cancer cells. Autophagy-IN-1 can induce apoptosis and cell cycle arrest. Autophagy-IN-1 significantly inhibits tumor growth in an HCT116 xenograft mouse model and with low toxicity. Autophagy-IN-1 can be used for researching colorectal cancer .

CSF1R-IN-3	c-Fms	Cancer
CSF1R-IN-3 (compound 21) is a potent and orally active CSF-1R inhibitor (IC₅₀=2.1 nM). CSF1R-IN-3 is a potent antiproliferative activity against colorectal cancer cells. CSF1R-IN-3 inhibits the progression of colorectal cancer by suppressing the migration of macrophages, reprograming M2-like macrophages to the M1 phenotype, and enhancing the antitumor immunity .

PRDX1-IN-2	Apoptosis ROS Kinase	Cancer
PRDX1-IN-2 (compound 15) is a selective inhibitor of the antioxidant enzyme Peroxiredoxin 1 (PRDX1) (IC₅₀=0.35 μM). PRDX1-IN-2 decreases the mitochondria membrane potential of SW620 cells, probably due to ROS induced by PRDX1 inhibition, leading to cell apoptosis. PRDX1-IN-2 can be used for colorectal cancer research .

EGFR-IN-59	EGFR Apoptosis	Cancer
EGFR-IN-59 (Compound 8c) is a EGFR inhibitor (IC₅₀=190 nM) and apoptosis inducer. EGFR-IN-59 exhibits cytotoxicity against non-small lung cancer cell lines (A549) and normal lung fibroblasts (WI38) with IC₅₀s of 8.62 and 52.6 µM, respectively. EGFR-IN-59 can be used for the research of various cancers such as non-small cell lung cancer (NSCLC), head and neck cancer, breast cancer and colorectal cancer .

MS934	PROTACs MEK	Cancer
MS934 is a novel improved VHL-recruiting MEK 1/2 PROTAC degrader. MS934 has anti-proliferation potency at inhibiting the growth of HT-29 cells with a GI₅₀ value of 0.023 μM. MS934 can be used for the research of variety of human cancers, such as melanoma, nonsmall cell lung cancer (NSCLC), colorectal cancer, primary brain tumors, and hepatocellular carcinoma . (Pink: Target protein ligand (HY-168288); Black: linker (HY-168289); Blue: E3 ligase ligand (HY-112078))

Bromosporine 3 Publications Verification	Epigenetic Reader Domain Apoptosis CDK HIV	Cancer
Bromosporine is a potent BET inhibitor with an IC₅₀ value of 2.1 μM for PCAF. Bromosporine can arrest cell cycle and induce apoptosis in cancer cells. Bromosporine exhibits excellent antitumor activity in xenograft mice model when combined with 5-FU (HY-90006). Bromosporine can increase CDK9 T-loop phosphorylation in HIV-1 latency models, resulting the protection of reactivate HIV-1 replication from latency. Bromosporine can be used to research colorectal cancer, acute myeloid leukemia (AML) and AIDS .

Wnt/β-catenin-IN-5	β-catenin PROTACs Histone Demethylase	Cancer
Wnt/β-catenin-IN-5 (Compound 4) is an inhibitor of the Wnt/β-catenin signaling pathway. Wnt/β-catenin-IN-5 eliminates colorectal cancer stem cells and inhibits tumor growth by suppressing the Wnt signaling pathway. PROTACs Wnt/β-catenin-IN-5, which is also a PROTAC based on IOX1, effectively induces the degradation of KDM3A and KDM3B (Target protein ligand (Pink): HY-12304; linker (Black): HY-22335; Conjugate of E3 ligase ligand and linker: HY-112599; E3 ligase (Blue): HY-41547) .

LM2I	Others Ser/Thr Protease	Cancer
LM2I is a derivative of Spinosyn A (SPA). LM2I is argininosuccinate synthase (ASS1) enzyme activator, and tumor inhibitor that directly interact with ASS1. LM2I has significant antiproliferative activity in seven colorectal cancer cell-lines and xenograft tumors of colorectal cancer. LM2I inhibits colorectal cancer cell growth via the EGFR pathway .

USP28-IN-2	Deubiquitinase	Cancer
USP28-IN-2 is a USP28 inhibitor (IC₅₀=0.3 μM) with high selectivity over USP2, USP7, USP8, USP9x, UCHL3 and UCHL5. USP28-IN-2 shows cytotoxicity against cancer cells, down-regulates the cellular level of c-Myc through ubiquitin-proteasome system. USP28-IN-2 also decreases the ankyrase-1/2 level in vitro. USP28-IN-2 enhance the sensitivity of colorectal cancer cells to Regorafenib (HY-10331) .

USP28-IN-3	Deubiquitinase	Cancer
USP28-IN-3 is a USP28 inhibitor (IC₅₀=0.1 μM) with high selectivity over USP2, USP7, USP8, USP9x, UCHL3 and UCHL5. USP28-IN-3 shows cytotoxicity against cancer cells, down-regulates the cellular level of c-Myc through ubiquitin-proteasome system. USP28-IN-3 also decreases the ankyrase-1/2 level in vitro. USP28-IN-3 enhance the sensitivity of colorectal cancer cells to Regorafenib (HY-10331) .

USP28-IN-4	Deubiquitinase	Cancer
USP28-IN-4 is a USP28 inhibitor (IC₅₀=0.04 μM) with high selectivity over USP2, USP7, USP8, USP9x, UCHL3 and UCHL5. USP28-IN-4 shows cytotoxicity against cancer cells, down-regulates the cellular level of c-Myc through ubiquitin-proteasome system. USP28-IN-4 also decreases the ankyrase-1/2 level in vitro. USP28-IN-4 enhance the sensitivity of colorectal cancer cells to Regorafenib (HY-10331) .

Darifenacin 5 Publications Verification UK-88525	mAChR p38 MAPK Akt	Neurological Disease Metabolic Disease Cancer
Darifenacin (UK-88525) is a selective and orally active M3 muscarinic receptor (M3R) antagonist with a pKi of 8.9. Darifenacin binds >20-fold more specifically to M3R than to other muscarinic receptors. Darifenacin can be used in the study of urinary incontinence and other symptoms of overactive bladder. Darifenacin inhibits tumor growth in colorectal cancer cells and has anti-tumor effects .

Darifenacin hydrobromide 5 Publications Verification UK-88525 hydrobromide	mAChR p38 MAPK Akt	Neurological Disease Metabolic Disease Cancer
Darifenacin (UK-88525) hydrobromide is a selective and orally active M3 muscarinic receptor (M3R) antagonist with a pKi of 8.9. Darifenacin hydrobromide binds >20-fold more specifically to M3R than to other muscarinic receptors. Darifenacin hydrobromide can be used in the study of urinary incontinence and other symptoms of overactive bladder. Darifenacin hydrobromide inhibits tumor growth in colorectal cancer cells and has anti-tumor effects .

Se-Aspirin Selenium-acetylsalicylic acid	NF-κB	Inflammation/Immunology
Se-Aspirin is a hybrid molecule of selenium and Aspirin (HY-14654). Se-Aspirin reduces the viability of cancer cell lines, particularly colorectal cancer cells .

Darifenacin (hydrobromide) (Standard) UK-88525 (hydrobromide) (Standard)	mAChR p38 MAPK Akt	Neurological Disease Metabolic Disease Cancer
Darifenacin (hydrobromide) (Standard) is the analytical standard of Darifenacin (hydrobromide). This product is intended for research and analytical applications. Darifenacin (hydrobromide) is a selective and orally active M3 muscarinic receptor (M3R) antagonist with a pKi of 8.9. Darifenacin (hydrobromide) binds >20-fold more specifically to M3R than to other muscarinic receptors. Darifenacin (hydrobromide) can be used in the study of urinary incontinence and other symptoms of overactive bladder. Darifenacin (hydrobromide) inhibits tumor growth in colorectal cancer cells and has anti-tumor effects .

SR18662	KLF	Cancer
SR18662 is a potent inhibitor of Krüppel-like factor five (KLF5) with an IC₅₀ of 4.4 nM and an analogue of ML264 (HY-19994) with improved inhibitory potency against colorectal cancer cells. SR18662 can be used for the study of colorectal cancer .

p53-MDM2-IN-6	MDM-2/p53 Apoptosis	Cancer
p53-MDM2-IN-6 (Compound 10a), a LSM-83177 hydrazone analog, is a potent p53-MDM2 inhibitor with an IC₅₀ value of 11.08 µg/mL. p53-MDM2-IN-6 arrests the cell cycle in the S phase and induces early and late Apoptosis with antiproliferative activity against HT29 cell lines with an IC₅₀ value of 10.44 µg/mL. p53-MDM2-IN-6 inhibits p53-MDM2 interaction with increment in p-53 level and decrease the expression of GST enzymes. p53-MDM2-IN-6 is promising for research of colorectal cancer .

Liensinine perchlorate 5+ Cited Publications	Apoptosis	Cardiovascular Disease Inflammation/Immunology Cancer
Liensinine Perchlorate is a constituent of?Nelumbo nucifera?Gaertn, with ani-hypertension and anti-cancer activities. Liensinine Perchlorate induces?colorectal cancer (CRC) cell apoptosis .

Sibrotuzumab BIBH 1; Anti-Human FAP Recombinant Antibody	FAP	Cancer
Sibrotuzumab (BIBH 1) is a humanized IgG1 monoclonal antibody targets fibroblast activation protein (FAP). Sibrotuzumab can be used for the research of colorectal cancer and non-small cell lung cancer (NSCLC) .

IGUANA-1	Aldehyde Dehydrogenase (ALDH)	Cancer
IGUANA-1 is a potent inhibitor of ALDH1B1, which is a mitochondrial enzyme that promotes colorectal and pancreatic cancer. IGUANA-1 has significant inhibition against cancer cells .

Garcinone E	Apoptosis	Cancer
Garcinone E is a natural xanthone found in the rind of the mangosteen fruit. Garcinone E induces apoptosis and inhibits cancer cell migration. Garcinone E has anticancer effects on different human cancer cell lines, including colorectal, breast, and hepatocellular carcinomas .

Palmitoylcarnitine chloride 1 Publications Verification	Endogenous Metabolite	Inflammation/Immunology Cancer
Palmitoylcarnitine chloride is a fatty acid-derived mitochondrial substrate, and selectively decreases cell survival in colorectal and prostate cancer cells by affecting on pro-inflammatory pathways, Ca ²⁺ influx, and DHT-like effects .

Mps-BAY1	Mps1 Apoptosis	Cancer
Mps-BAY1 is an MPS1 inhibitor with anticancer activity. Mps-BAY1 inhibits cell proliferation and induces apoptosis by activating mitotic catastrophe in cancer cells, generating global aneuploidy and polyploidy. Mps-BAY1 can be used in the study of colorectal cancer and cervical cancer .

Cyclosomatostatin	Somatostatin Receptor	Cancer
Cyclosomatostatin is a potent somatostatin (SST) receptor antagonist. Cyclosomatostatin can inhibit somatostatin receptor type 1 (SSTR1) signaling and decreases cell proliferation, ALDH+ cell population size and sphere-formation in colorectal cancer (CRC) cells .

Enterodiol	Apoptosis Endogenous Metabolite	Cancer
Enterodiol is transformed by human intestinal bacteria from lignans contained in various whole-grain cereals, nuts, legumes, flaxseed, and vegetables. Enterodiol has an apoptotic effect in colorectal cancer (CRC) cells. Anti-cancer activities .

YB-0158 2 Publications Verification Wnt pathway inhibitor 2	Wnt Apoptosis	Cancer
YB-0158 (Wnt pathway inhibitor 2) is a reverse-turn peptidomimetic and a potent colorectal cancer stem cell (CSC) targeting agent. YB-0158 disrupts Sam68-Src interactions and induces apoptosis in CRC cells. Anti-cancer activities .

Cyclosomatostatin TFA	Somatostatin Receptor	Cancer
Cyclosomatostatin TFA is a potent somatostatin (SST) receptor antagonist. Cyclosomatostatin TFA can inhibit somatostatin receptor type 1 (SSTR1) signaling and decreases cell proliferation, ALDH+ cell population size and sphere-formation in colorectal cancer (CRC) cells .

Multi-kinase-IN-1	Apoptosis c-Met/HGFR PDGFR Src TAM Receptor	Cancer
Multi-kinase-IN-1 (Compound 11k) is a potent kinase inhibitor with antitumor activity. Multi-kinase-IN-1 induces cell apoptosis, and can be studied for colorectal cancer .

KHKI-01128	AMPK	Cancer
KHKI-01128 is a NUAK2 inhibitor, with an IC₅₀ of 0.024 μM. KHKI-01128 exhibits potent anticancer activity against SW480 colorectal cancer cells .

Cat. No.	Product Name

HY-L103

Anti-Colorectal Cancer Compound Library

1,666 compounds

Colorectal cancer (CRC), also known as bowel cancer, colon cancer, or rectal cancer, arises as adenocarcinoma from glandular epithelial cells of the large intestine comprised of the colon and rectum. The majority of cases of CRC are sporadic and result from risk factors, such as a sedentary lifestyle, obesity, processed diets, alcohol consumption and smoking. CRC is also a common preventable cancer.

Studies showed several cellular signaling pathways dysregulated in CRC, leading to the onset of malignant phenotypes. Therefore, it is necessary to analyze the signaling pathways involved in the occurrence and development of colorectal cancer to study the progression and drug treatment of colorectal cancer. Among them, Wnt/β-catenin, p53, TGF-β/SMAD, NF-κB, Notch, VEGF and other target genes and signaling pathways are the focus of research. MCE offers a unique collection of 1,666 compounds with identified and potential anti-colorectal cancer activity. MCE anti-colorectal cancer compound library is a useful tool for anti-colorectal cancer drugs screening and other related research.

Cat. No.	Product Name	Type

HY-D1456

TEPC466

Fluorescent Dyes/Probes

TEPC466 is a novel TEPP-46-based aggregation-induced emission (AIE) probe. TEPC466 shows a high degree of selectivity and sensitivity for the detection of PKM2 protein via the AIE effect. EPC466 can be used for the detection of PKM2. TEPC466 is successfully applied in imaging the PKM2 protein in colorectal cancer cells with low toxicity. TEPC466 is a useful tool for cancer diagnosis and research .

Cat. No.	Product Name	Target	Research Area

HY-P1201

Cyclosomatostatin	Somatostatin Receptor	Cancer
Cyclosomatostatin is a potent somatostatin (SST) receptor antagonist. Cyclosomatostatin can inhibit somatostatin receptor type 1 (SSTR1) signaling and decreases cell proliferation, ALDH+ cell population size and sphere-formation in colorectal cancer (CRC) cells .

HY-P1201A

Cyclosomatostatin TFA	Somatostatin Receptor	Cancer
Cyclosomatostatin TFA is a potent somatostatin (SST) receptor antagonist. Cyclosomatostatin TFA can inhibit somatostatin receptor type 1 (SSTR1) signaling and decreases cell proliferation, ALDH+ cell population size and sphere-formation in colorectal cancer (CRC) cells .

HY-P2569

Malformin A1	Apoptosis	Cancer
Malformin A1, a cyclic pentapeptide isolated from Aspergillus niger, possess a range of bioactive properties including antibacterial activity. Malformin A1 shows potent cytotoxic activities on human colorectal cancer cells. Malformin A1 induces apoptosis by activating PARP, caspase 3, -7, and -9 .

HY-P2269

MAIT-203	Peptides	Cancer
MAIT-203, a cyclopentyalanin-derived peptidomimetic, potently inhibits the interaction of adenomatous polyposis coli (APC) and Asef (RhoGEF4), but not APC-Sam68 or APC-striatin interactions. MAIT-203 binds APC-ARM with a K_i of 0.015 μM and a K_d of 0.036 μM. MAIT-203 significantly represses the migration and invasion of colorectal cancer cells.

Cat. No.	Product Name	Target	Research Area

HY-P99011

Cibisatamab	CD3	Cancer
Cibisatamab (CEA-TCB), a T cell bispecific antibody, binds Carcino-Embryonic Antigen (CEA) on cancer cells and CD3 on T cells. Cibisatamab (CEA-TCB) triggers T cell killing of cancer cell lines expressing moderate to high levels of CEA at the cell surface. Cibisatamab (CEA-TCB) can be used for colorectal cancer research .

HY-P99406

Petosemtamab MCLA 158	EGFR	Cancer
Petosemtamab (MCLA 158) is an anti- EGFR (K_d: 0.22 nM) and anti-LGR5 (K_d: 0.86 nM) monoclonal antibody (mAb). Petosemtamab leads to EGFR signaling blockade and receptor degradation in LGR5+ cancer cells. Petosemtamab can be used in the research of solid tumors, such as head and neck squamous cell carcinoma (HNSCC), metastatic colorectal cancer (CRC) .

HY-P99275

Patritumab 1 Publications Verification Human Anti-ERBB3 Recombinant Antibody	EGFR Akt ERK PARP Survivin	Cancer
Patritumab (Human Anti-ERBB3 Recombinant Antibody) is a neutralizing monoclonal antibody to ERBB3. Patritumab shows a synergy with Cetuximab (HY-P9905), potently inhibits the phosphorylation of EGFR, HER2, HER3, ERK, and AKT. Patritumab also induces cell apoptosis and suppresses the growth of pancreatic, non-small cell lung cancer, and colorectal cancer xenograft tumors .

HY-P99269

Sibrotuzumab BIBH 1; Anti-Human FAP Recombinant Antibody	FAP	Cancer
Sibrotuzumab (BIBH 1) is a humanized IgG1 monoclonal antibody targets fibroblast activation protein (FAP). Sibrotuzumab can be used for the research of colorectal cancer and non-small cell lung cancer (NSCLC) .

HY-P99215

Parsatuzumab Anti-EGFL7; RG 7414	VEGFR	Cancer
Parsatuzumab (Anti-EGFL7; RG 7414) is a humanized monoclonal antibody, acts as an immunomodulator and binds to EGFL7. Parsatuzumab selectively blocks the interaction between EGFL7 and endothelial cells, potentially inhibiting vascular regrowth and reducing vascular endothelial growth factor (VEGF) inhibition .

Cat. No.	Product Name	Chemical Structure

HY-16560S

Camptothecin-d5

Camptothecin-d₅ is the deuterium labeled Camptothecin. Camptothecin (CPT), a kind of alkaloid, is a DNA topoisomerase I (Topo I) inhibitor with an IC50 of 679 nM[1]. Camptothecin (CPT) exhibits powerful antineoplastic activity against colorectal, breast, lung and ovarian cancers, modulates hypoxia-inducible factor-1α (HIF-1α) activity by changing microRNAs (miRNA) expression patterns in human cancer cells[2][3].

HY-13653S1

(-)-Epigallocatechin Gallate-d4

(-)-Epigallocatechin Gallate-d4 (EGCG-d4) is the deuterium labeled (-)-Epigallocatechin Gallate (HY-13653). (-)-Epigallocatechin Gallate (EGCG) is a major polyphenol in green tea, which can inhibit cell proliferation and induce cell apoptosis. (-)-Epigallocatechin Gallate inhibits glutamate dehydrogenase 1/2 (GDH1/2, GLUD1/2) activity. (-)-Epigallocatechin Gallate has a potent anticancer, antioxidant and anti-inflammatory properties against various types of cancers such as colorectal cancer, myeloid leukemia, thyroid carcinoma .

HY-B1490AS3

Imipramine-d4-1

Imipramine-d4-1 is the deuterium labeled Imipramine (HY-W010179). Imipramine is an orally active tertiary amine tricyclic antidepressant. Imipramine is a Fascin1 inhibitor with antitumor activities. Imipramine also inhibits serotonin transporter with an IC₅₀ value of 32 nM. Imipramine stimulates U-87MG glioma cells autophagy and induces HL-60 cell apoptosis. Imipramine shows neuroprotective and immunomodulatory effects .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks